The new joint EAS/ESC guidelines for the management of dyslipidaemias

Abstract

The guidelines for the ESC/EAS Guidelines for the management f dyslipidaemias produced by the task force for the management f dyslipidaemias of the European Society of Cardiology (ESC) and he European Atherosclerosis Society (EAS) are published in this ssue of Atherosclerosis. It is the first time that the EAS and the SC jointly have worked together to produce such a relevant clinial approach, that should continue the work of recent years as one f the major pillars in the prevention of Cardiovascular diseases CVD). The challenge has been, as in all previous guidelines, to sumarize the large body of evidence into recommendations that can e managed by the clinician, while at the same time providing sufcient insight to provide guidance for the treatment of some of the ess frequent dyslipidaemias that also contribute to the burden of VD. This is reflected in the guidelines, where on one side the pivotal ole of LDL cholesterol in contributing to CVD risk is emphasised ut, on theotherhand, additional guidance is providedas to the role f other lipid fractions such as HDL, plasma Triglycerides, Lp(a) and on-HDL cholesterol, while also the key position of apo B as part of he diagnostic armoury, is highlighted. A further additional novelty in the assessment of global risk is hat the charts and algorithms for the calculation of global risk have ncorporated HDL-C as a key riskmodulator, in agreementwith the oncept that many factors impinge and contribute to CVD risk. A ore detailed breakdown of risk evaluation is recommended, that